Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors

Meili Zhang, Zhengsheng Yao, Zhuo Zhang, Kayhan Garmestani, Carolyn K. Goldman, Jeffrey V. Ravetch, John Edward Janik, Martin W. Brechbiel, Thomas A. Waldmann

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

CD30 is a member of the tumor necrosis factor receptor family. Overexpression of CD30 on some neoplasms versus its limited expression on normal tissues makes this receptor a promising target for antibody-based therapy. Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by the strong expression of CD30. We investigated the therapeutic efficacy of HeFi-1, a mouse IgG1 monoclonal antibody, which recognizes the ligand-binding site on CD30, and humanized anti-Tac antibody (daclizumab), which recognizes CD25, in a murine model of human ALCL. The ALCL model was established by intravenous injection of karpas299 cells into nonobese diabetic/severe combined immunodeficient (SCID/NOD) wild-type or SCID/NOD Fc receptor common γ chain-deficient (FcRγ-/-) mice. HeFi-1, given at a dose of 100 μg weekly for 4 weeks, significantly prolonged survival of the ALCL-bearing SCID/NOD wild-type and SCID/NOD FcRγ-/- mice (P < .01) as compared with the control groups. In vitro studies showed that HeFi-1 inhibited the proliferation of karpas299 cells, whereas daclizumab did not inhibit cell proliferation. We demonstrated that the expression of FcRγ on polymorphonuclear leukocytes and monocytes was not required for HeFi-1-mediated tumor growth inhibition in vivo, although it was required for daclizumab.

Original languageEnglish (US)
Pages (from-to)705-710
Number of pages6
JournalBlood
Volume108
Issue number2
DOIs
StatePublished - Jul 15 2006

Fingerprint

Anaplastic Large-Cell Lymphoma
Fc Receptors
Monoclonal Antibodies
Bearings (structural)
Antibodies
Tumor Necrosis Factor Receptors
Cell Proliferation
Cell proliferation
Antibodies, Monoclonal, Humanized
SCID Mice
Tumors
Therapeutics
Immunoglobulin G
Binding Sites
Intravenous Injections
Non-Hodgkin's Lymphoma
Tissue
Ligands
Monocytes
Anti-Idiotypic Antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. / Zhang, Meili; Yao, Zhengsheng; Zhang, Zhuo; Garmestani, Kayhan; Goldman, Carolyn K.; Ravetch, Jeffrey V.; Janik, John Edward; Brechbiel, Martin W.; Waldmann, Thomas A.

In: Blood, Vol. 108, No. 2, 15.07.2006, p. 705-710.

Research output: Contribution to journalArticle

Zhang, M, Yao, Z, Zhang, Z, Garmestani, K, Goldman, CK, Ravetch, JV, Janik, JE, Brechbiel, MW & Waldmann, TA 2006, 'Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors', Blood, vol. 108, no. 2, pp. 705-710. https://doi.org/10.1182/blood-2005-11-4607
Zhang, Meili ; Yao, Zhengsheng ; Zhang, Zhuo ; Garmestani, Kayhan ; Goldman, Carolyn K. ; Ravetch, Jeffrey V. ; Janik, John Edward ; Brechbiel, Martin W. ; Waldmann, Thomas A. / Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. In: Blood. 2006 ; Vol. 108, No. 2. pp. 705-710.
@article{085819ac86194dcab042f68e8369e207,
title = "Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors",
abstract = "CD30 is a member of the tumor necrosis factor receptor family. Overexpression of CD30 on some neoplasms versus its limited expression on normal tissues makes this receptor a promising target for antibody-based therapy. Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by the strong expression of CD30. We investigated the therapeutic efficacy of HeFi-1, a mouse IgG1 monoclonal antibody, which recognizes the ligand-binding site on CD30, and humanized anti-Tac antibody (daclizumab), which recognizes CD25, in a murine model of human ALCL. The ALCL model was established by intravenous injection of karpas299 cells into nonobese diabetic/severe combined immunodeficient (SCID/NOD) wild-type or SCID/NOD Fc receptor common γ chain-deficient (FcRγ-/-) mice. HeFi-1, given at a dose of 100 μg weekly for 4 weeks, significantly prolonged survival of the ALCL-bearing SCID/NOD wild-type and SCID/NOD FcRγ-/- mice (P < .01) as compared with the control groups. In vitro studies showed that HeFi-1 inhibited the proliferation of karpas299 cells, whereas daclizumab did not inhibit cell proliferation. We demonstrated that the expression of FcRγ on polymorphonuclear leukocytes and monocytes was not required for HeFi-1-mediated tumor growth inhibition in vivo, although it was required for daclizumab.",
author = "Meili Zhang and Zhengsheng Yao and Zhuo Zhang and Kayhan Garmestani and Goldman, {Carolyn K.} and Ravetch, {Jeffrey V.} and Janik, {John Edward} and Brechbiel, {Martin W.} and Waldmann, {Thomas A.}",
year = "2006",
month = "7",
day = "15",
doi = "10.1182/blood-2005-11-4607",
language = "English (US)",
volume = "108",
pages = "705--710",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors

AU - Zhang, Meili

AU - Yao, Zhengsheng

AU - Zhang, Zhuo

AU - Garmestani, Kayhan

AU - Goldman, Carolyn K.

AU - Ravetch, Jeffrey V.

AU - Janik, John Edward

AU - Brechbiel, Martin W.

AU - Waldmann, Thomas A.

PY - 2006/7/15

Y1 - 2006/7/15

N2 - CD30 is a member of the tumor necrosis factor receptor family. Overexpression of CD30 on some neoplasms versus its limited expression on normal tissues makes this receptor a promising target for antibody-based therapy. Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by the strong expression of CD30. We investigated the therapeutic efficacy of HeFi-1, a mouse IgG1 monoclonal antibody, which recognizes the ligand-binding site on CD30, and humanized anti-Tac antibody (daclizumab), which recognizes CD25, in a murine model of human ALCL. The ALCL model was established by intravenous injection of karpas299 cells into nonobese diabetic/severe combined immunodeficient (SCID/NOD) wild-type or SCID/NOD Fc receptor common γ chain-deficient (FcRγ-/-) mice. HeFi-1, given at a dose of 100 μg weekly for 4 weeks, significantly prolonged survival of the ALCL-bearing SCID/NOD wild-type and SCID/NOD FcRγ-/- mice (P < .01) as compared with the control groups. In vitro studies showed that HeFi-1 inhibited the proliferation of karpas299 cells, whereas daclizumab did not inhibit cell proliferation. We demonstrated that the expression of FcRγ on polymorphonuclear leukocytes and monocytes was not required for HeFi-1-mediated tumor growth inhibition in vivo, although it was required for daclizumab.

AB - CD30 is a member of the tumor necrosis factor receptor family. Overexpression of CD30 on some neoplasms versus its limited expression on normal tissues makes this receptor a promising target for antibody-based therapy. Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by the strong expression of CD30. We investigated the therapeutic efficacy of HeFi-1, a mouse IgG1 monoclonal antibody, which recognizes the ligand-binding site on CD30, and humanized anti-Tac antibody (daclizumab), which recognizes CD25, in a murine model of human ALCL. The ALCL model was established by intravenous injection of karpas299 cells into nonobese diabetic/severe combined immunodeficient (SCID/NOD) wild-type or SCID/NOD Fc receptor common γ chain-deficient (FcRγ-/-) mice. HeFi-1, given at a dose of 100 μg weekly for 4 weeks, significantly prolonged survival of the ALCL-bearing SCID/NOD wild-type and SCID/NOD FcRγ-/- mice (P < .01) as compared with the control groups. In vitro studies showed that HeFi-1 inhibited the proliferation of karpas299 cells, whereas daclizumab did not inhibit cell proliferation. We demonstrated that the expression of FcRγ on polymorphonuclear leukocytes and monocytes was not required for HeFi-1-mediated tumor growth inhibition in vivo, although it was required for daclizumab.

UR - http://www.scopus.com/inward/record.url?scp=33745941325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745941325&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-11-4607

DO - 10.1182/blood-2005-11-4607

M3 - Article

C2 - 16551968

AN - SCOPUS:33745941325

VL - 108

SP - 705

EP - 710

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -